Mengis Capital Management, Inc.

Position in NVO — Novo Nordisk A S

CIK 1609674 PORTLAND, OR

Position in NVO

as of Jun 30, 2026 · filed Jul 28, 2026 Compact

Position Value

$3,362,751

+$776,874 QoQ

Shares Held

70,145

-0.3% QoQ

Ownership

0.002%

of shares outstanding

% of Portfolio

0.97%

of 13F equity value

Holder Rank

#281

of 1,348 holders

Holding Since

Sep 2025

4 quarters on record

Voting authority Sole 97% Shared 0% None 3%

Healthcare · as of Jun 30, 2026

Mengis Capital Management, Inc. holds $32,051,953 across 6 Drug Manufacturers - General names. NVO ranks #3 (10.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	LLY	ELI LILLY & Co	10,186	$12,217,394
2	JNJ	Johnson & Johnson	40,975	$10,406,420
3	NVO	Novo Nordisk A S This page	70,145	$3,362,751
4	BMY	Bristol Myers Squibb Co	40,778	$2,349,628
5	AMGN	Amgen Inc	6,047	$2,189,739
6	PFE	Pfizer Inc	63,373	$1,526,021

4 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,362,751	70,145	-0.3%	Shares	Sole	2026-07-28
2026-03-31	$2,585,877	70,364	+5.5%	Shares	Sole	2026-05-12
2025-12-31	$3,393,390	66,694	+303.2%	Shares	Sole	2026-03-05
2025-09-30	$917,804	16,540	—	Shares	Sole	2025-11-12
No filing history on record for this holder in this stock.